In this episode of The Skin Science Podcast, Thomas M. Hitchcock, Ph.D., Chief Science Officer, speaks with David Weir, MSN, APRN, NP-C, about exosomes and the challenge of limited substantiated science.
The Skin Science Podcast is intended to provide listeners with information regarding various topics in the field of skin science. None of the content in this podcast should be interpreted or construed as professional or medical advice. Further, the views and opinions expressed by guests are their own and do not represent those of Crown Laboratories, Inc., and the appearance of any guest on the podcast does not imply an endorsement of the guest or any particular entity they represent.
0:00 Introduction
0:55 Guest, David Weir
3:00 Exosomes in the aesthetic industry
7:12 Studies with exosomes
10:40 Questions of safety and dosage
12:50 Exosome sources
18:10 How genetics play into exosome contents
24:40 Responsibilities of consumers, providers, and companies
28:40 What questions patients should ask about exosome products
33:40 Concluding statements
In this episode of The Skin Science Podcast, Thomas M. Hitchcock, Ph.D., Chief Science Officer, speaks with David Weir, MSN, APRN, NP-C, about exosomes and the challenge of limited substantiated science.
The Skin Science Podcast is intended to provide listeners with information regarding various topics in the field of skin science. None of the content in this podcast should be interpreted or construed as professional or medical advice. Further, the views and opinions expressed by guests are their own and do not represent those of Crown Laboratories, Inc., and the appearance of any guest on the podcast does not imply an endorsement of the guest or any particular entity they represent.
0:00 Introduction
0:55 Guest, David Weir
3:00 Exosomes in the aesthetic industry
7:12 Studies with exosomes
10:40 Questions of safety and dosage
12:50 Exosome sources
18:10 How genetics play into exosome contents
24:40 Responsibilities of consumers, providers, and companies
28:40 What questions patients should ask about exosome products
33:40 Concluding statements